Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

Acromegaly: An Endocrine Society Clinical Practice Guideline

(2014) Laurence Katznelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

(2014) A. Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly

(2014) G. Lombardi et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Short- and long-term changes of quality of life in patients with acromegaly: Results from a prospective study

(2014) C. Sardella et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Expert consensus document: A consensus on the medical treatment of acromegaly

(2014) Andrea Giustina et al.   Nature Reviews Endocrinology

Health-related quality of life and psychiatric symptoms improve effectively within a short time in patients surgically treated for pituitary tumors—a longitudinal study of 106 patients

(2013) Monika Milian et al.   ACTA NEUROCHIRURGICA

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update

(2013) Laurence Katznelson et al.   Endocrine Practice

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

(2013) Philippe J. Caron et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Biochemical and quality of life responses to octreotide-LAR in acromegaly

(2013) Ruth Mangupli et al.   Pituitary

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

(2012) Mark R Postma et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly

(2011) Z. Karaca et al.   CLINICAL ENDOCRINOLOGY

Affected Illness Perceptions and the Association with Impaired Quality of Life in Patients with Long-Term Remission of Acromegaly

(2011) Jitske Tiemensma et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical, quality of life, and economic value of acromegaly disease control

(2011) A. Ben-Shlomo et al.   Pituitary

Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR

(2010) J. Schopohl et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

The German ACROSTUDY: past and present

(2009) M Buchfelder et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly

(2008) Annamaria Colao et al.   CLINICAL ENDOCRINOLOGY

Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance

(2008) Maria P Matta et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant

(2008) S. J. C. M. M. Neggers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM